These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25950595)

  • 21. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study.
    Hoffman K; Peyton ML; Sumner M
    J Addict Med; 2017; 11(3):217-223. PubMed ID: 28353467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
    Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
    JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms.
    Streck JM; Ochalek TA; Badger GJ; Sigmon SC
    Exp Clin Psychopharmacol; 2018 Aug; 26(4):403-409. PubMed ID: 29939049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DYNAMICS OF OPIOID SUBSTITUTION TREATMENTIN DIFFERENT INITIAL SUBSTANCE USER OPIOID DEPENDENT PATIENTS.
    Todadze Kh; Mosia S
    Georgian Med News; 2016 May; (254):56-61. PubMed ID: 27348169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults.
    Peck KR; Ochalek TA; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2020 Mar; 208():107879. PubMed ID: 31991327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review and meta-analysis of changes in quality of life following initiation of buprenorphine for opioid use disorder.
    Golan OK; Totaram R; Perry E; Fortson K; Rivera-Atilano R; Entress R; Golan M; Andraka-Christou B; Whitaker D; Pigott T
    Drug Alcohol Depend; 2022 Jun; 235():109445. PubMed ID: 35430522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
    Lofwall MR; Walsh SL; Nunes EV; Bailey GL; Sigmon SC; Kampman KM; Frost M; Tiberg F; Linden M; Sheldon B; Oosman S; Peterson S; Chen M; Kim S
    JAMA Intern Med; 2018 Jun; 178(6):764-773. PubMed ID: 29799968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.
    Wiegand TJ
    J Med Toxicol; 2016 Mar; 12(1):64-70. PubMed ID: 26574020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users.
    Nielsen S; Hillhouse M; Thomas C; Hasson A; Ling W
    J Addict Med; 2013; 7(1):33-8. PubMed ID: 23222095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
    Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
    Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of behavioral treatment conditions in buprenorphine maintenance.
    Ling W; Hillhouse M; Ang A; Jenkins J; Fahey J
    Addiction; 2013 Oct; 108(10):1788-98. PubMed ID: 23734858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
    Amato P
    Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A trial of integrated buprenorphine/naloxone and HIV clinical care.
    Sullivan LE; Barry D; Moore BA; Chawarski MC; Tetrault JM; Pantalon MV; O'Connor PG; Schottenfeld RS; Fiellin DA
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S184-90. PubMed ID: 17109305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Definitive urine drug testing in office-based opioid treatment: a literature review.
    Barthwell AG; Allgaier J; Egli K
    Crit Rev Toxicol; 2018 Nov; 48(10):829-852. PubMed ID: 30794024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.
    Rosenthal RN; Lofwall MR; Kim S; Chen M; Beebe KL; Vocci FJ;
    JAMA; 2016 Jul; 316(3):282-90. PubMed ID: 27434441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short term health-related quality of life improvement during opioid agonist treatment.
    Nosyk B; Bray JW; Wittenberg E; Aden B; Eggman AA; Weiss RD; Potter J; Ang A; Hser YI; Ling W; Schackman BR
    Drug Alcohol Depend; 2015 Dec; 157():121-8. PubMed ID: 26511766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.